GMAB – genmab a/s - american depositary shares (US:NASDAQ)

News

BioNJ Unveils "Time Off for Clinical Trials" Initiative [Yahoo! Finance]
Genmab A/S (NASDAQ: GMAB) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $46.00.
High Growth Tech Stocks To Watch In November 2024 [Yahoo! Finance]
Genmab Announces Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
Genmab Announces Financial Results for the First Nine Months of 2024
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com